BIO972 Israel. Science. Community.

Teva Pharmaceutical Industries Ltd. (NYSE,TASE:TEVA) has signed an agreement to sell its Sellersville, Pennsylvania facility to G&W Laboratories, Inc., salvaging 280 employees’  jobs and further streamlining its own operations by reducing excess manufacturing capacity. The sale is part of the Company’s previously announced ...

Scientists hope the discovery of 1,500-year-old grape seeds may help resurrect the Byzantine Empire’s world-renowned “Wine of the Negev” “The Wine of the Negev” was historically one of the finest and most renowned wines of the Byzantine Empire, but its composition was ...

Rehovot-based Evogene is establishing an R&D facility in St. Louis, Missouri. The central focus of the facility will be Evogene’s existing insect control program and it will be headed by Dr. James Presnail, Ph.D. The company has received economic incentives from the Missouri Department ...

MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announced that Gal Cohen, MediWound’s Chief Executive Officer, will ring the NASDAQ Stock Market Closing Bell today (February 5, 2015) in ...

Evogene is incorporating its new gene optimization program into its long-term collaboration with Monsanto. The addition comes after Evogene identified and validated more than 1,000 genes that have entered Monsanto’s product pipeline which improve yield and stress tolerance. Evogene’s computational technology system has the potential to ...

After its stock dropped over 80% last year with failed Phase III trial results, Alcobra has raised approximately $27.9 million in a public offering of ordinary shares. The full over allotment option was exercised by the underwriters: 975,000 of the 7.5 million ...

Therapix Biosciences, a biopharma company focused on cannabinoid drugs, has signed a binding term sheet with Dekel Pharmaceuticals for the exclusive worldwide right to develop, manufacture and commercialize combination drug therapies based on Dekel’s technology. The technology is based on the “entourage effect” ...

Total revenue in the range of $72 to $74 million, up 20% to 24% y/y (pro-forma excluding Syneron Beauty), including approximately 50% product revenue growth in North America Strong UltraShape full commercial launch in U.S. with more than 50 systems ...

First-in-human Phase 1 trial expected to commence in Q1 2015 MISGAV, Israel–(BUSINESS WIRE)–cCAM Biotherapeutics, a biopharmaceutical company focused on the discovery and development of novel cancer immunotherapies, announced today that it has received approval form the US Food and Drug ...

Patent Covers Methods for Using Vibration to Harvest Large Yields of Viable Cells Grown With Three-Dimensional Technology HAIFA, Israel, Jan. 6, 2015 (GLOBE NEWSWIRE) — Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, announced today that ...